ContraFect Corporation to Present at BioCentury's 21st

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ContraFect Corporation to Present at BioCentury's 21st Annual NewsMakers in the Biotech Industry Conference

YONKERS, NEW YORK--(Marketwired - Sep 19, 2014) - ContraFect Corporation ( NASDAQ : CFRX ) ( NASDAQ : CFRXW ) ( NASDAQ : CFRXZ ), a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, announced today that Julia P. Gregory, the Company's chief executive officer and Barry Kappel, the Company's senior vice president of business development, will present a corporate overview at BioCentury's 21 st Annual NewsMakers in the Biotech Industry Conference at the Millennium Broadway Hotel in New York, NY on Friday, September 26 at 8:30 AM EST. Ms. Gregory and Dr. Kappel will discuss ContraFect's lead programs, CF-301, which provides a novel approach to the treatment of drug-resistant Staphylococcus aureus infections and CF-404, a universal treatment for life-threatening influenza infections.

The presentation will be available as a webcast for a limited time. To access via the Company's website, please go to www.contrafect.com . To access the webcast directly, please use the following URL: https://www.webcaster4.com/Webcast/Page/392/5771 .

About ContraFect:

ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. We intend to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (drug-resistant staphylococcus bacteria) and influenza.

About BioCentury NewsMakers in the Biotech Industry Conference:

NewsMakers presents a hand-picked group of public biotech companies whose corporate and regulatory milestones will drive stock prices. NewsMakers is recognized as the industry's key venue for companies to take their story to Wall Street each Fall. Thus, NewsMakers remains the best opportunity for business development executives and key members of the institutional investment and analyst communities to compare notes and assess the industry landscape.

FORWARD-LOOKING STATEMENTS

This press release contains, and our officers and representatives may make from time to time, "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar references to future periods. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including those detailed in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact: Barry Kappel, Ph.D., MBA SVP Business Development Tel: 914-207-2300 E-Mail: Email Contact or visit: www.contrafect.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 22

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 19

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 12

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 16

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 21

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 9

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 10

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading

Top 5 Most Recently Viewed Articles

Niterra and Rackspace: Seamless Migration to Google Cloud

Updated Category News Views 126

Niterra and Rackspace: A Strategic Partnership for Cloud Migration Niterra EMEA GmbH has taken a monumental step in its digital transformation journey by partnering with Rackspace Technology. This collaboration aims to enhance operational efficiency through a swift migration to Google Cloud, capitalizing on Rackspace's extensive expertise in handling business-critical...

Continue Reading
Sweden Procures Four C-390 Millennium Aircraft from Embraer

Updated Category News Views 123

Sweden's Announcement on C-390 Millennium Acquisition In a significant development for military aviation, Sweden has officially committed to acquiring four C-390 Millennium multi-mission aircraft from Embraer. This strategic move is expected to enhance Sweden's defense capabilities and interoperability within NATO. Details of the Agreement The acquisition announcement...

Continue Reading
MindMed Initiates Phase 3 Study for MM120 in Anxiety Treatment

Updated Category News Views 332

MindMed Begins Journey with Phase 3 Study of MM120 Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has crossed a significant milestone in its mission to provide breakthrough treatments for brain health disorders. The clinical-stage biopharmaceutical company has announced that the first patient is now dosed in its pivotal Phase 3 Voyage study of MM120 Orally Disintegrating...

Continue Reading
Global Office Furniture Market Set to Expand Significantly

Updated Category News Views 62

Growth Overview of the Office Furniture Market The global office furniture market is currently experiencing steady growth, fueled by the rising popularity of flexible and hybrid work environments. This shift is creating a strong demand for adaptable and ergonomic furniture that works well in both home and office contexts. As businesses evolve and expand, there’s an...

Continue Reading
Understanding Fiscal Dominance and Its Impact on Bond Markets

Updated Category News Views 467

Understanding Fiscal Dominance and Its Effects Fiscal dominance is an increasingly important concept in today's economic discussions, especially for those keen on understanding market dynamics. This economic principle involves a scenario where ongoing primary fiscal deficits stimulate nominal growth while the Central Bank maintains a loose monetary policy, failing to...

Continue Reading